Document:

Sixth Amendment to the Second Amended and Restated Loan Agreement

 Exhibit 10.38 

SIXTH AMENDMENT 
 TO

 SECOND AMENDED AND RESTATED LOAN AGREEMENT 

This Sixth Amendment to Second Amended and Restated Loan Agreement (this “Amendment”) is dated February 28, 2017, by and
among: (i) RTI Surgical, Inc., a Delaware corporation formerly known as RTI Biologics, Inc. (“Borrower”); (ii) TD Bank, N.A., a national banking association, as administrative agent for the Lenders (in such capacity,
including any successor thereto, the “Administrative Agent”); and (iii) each of the Lenders from time to time party to the Loan Agreement. 

Capitalized terms used herein without definition shall have the respective meaning assigned to such terms in that certain Second Amended and
Restated Loan Agreement, dated July 16, 2013, by and among Borrower, the Administrative Agent and the Lenders, as amended by: (i) that certain First Amendment to Second Amended and Restated Loan Agreement, dated December 30, 2013;
(ii) that certain Second Amendment to Second Amended and Restated Loan Agreement, dated October 15, 2014; (iii) that certain Third Amendment to Second Amended and Restated Loan Agreement, dated June 29, 2015, (iv) that
certain Fourth Amendment to Second Amended and Restated Loan Agreement, dated June 29, 2016, and (v) that certain Fifth Amendment to Second Amended and Restated Loan Agreement, dated November 7, 2016 (collectively, the “Loan
Agreement”). 
 Borrower, the Administrative Agent and the Lenders are party to the Loan Agreement pursuant to which the Lenders
have extended credit to Borrower on the terms set forth in the Loan Agreement. 
 Borrower, the Administrative Agent and the Lenders desire
to amend the Loan Agreement to modify the definition of “Extraordinary Expenses” in Section 1.1(eee) of the Loan Agreement and to increase to 300 basis points the LIBOR Spread applicable when Borrower’s financial performance
under its Leverage Ratio is greater than 3.0x. 
 Borrower, the Administrative Agent and the Lenders are willing to make such amendments to
the Loan Agreement on the terms and conditions set forth in this Amendment. 
 Now, therefore, the parties hereto, intending to be legally
bound, hereby agree as follows: 
 SECTION 1 

AMENDMENTS TO LOAN AGREEMENT 

1.1     Amendment of Section 1.1(eee), Definition of Extraordinary Expenses. Section 1.1(eee) of the Loan
Agreement is deleted in its entirety and the following new Section 1.1(eee) is substituted in its place: 

        (eee)    “Extraordinary Expenses” means
any one-time expenses such as: (i) non-cash intangible asset impairment charges; provided, however, the amount of such charges for purposes of determining Consolidated EBITDA under this Agreement is subject to review and approval
of Administrative Agent and Lenders; (ii) expenses related to Strategic Review costs and the Hutchinson retirement for the period of October 1, 2016 through December 31, 2016, not to exceed Seven Hundred Ninety-Seven Thousand and
00/100 Dollars ($797,000.00); (iii) reorganization costs for the period of July 1, 2016 through September 30, 2016, not to exceed Three Million Five Hundred Fifty Thousand and 00/100 Dollars ($3,550,000.00); (iv) the actual
amount of severance/reorganization charges for the period of January 1, 2017 through March 31, 2017, not to exceed Four Million and 00/100 Dollars ($4,000,000.00); and (v) one-time, non-cash charges for inventory write-downs and
Germany asset impairment for the period of October 1, 2016 through December 31, 2016, not to exceed Fourteen Million Eight Hundred Twenty-Seven Thousand and 00/100 Dollars ($14,827,000.00). 

 1.2     Amendment of Section 2.4(c), LIBOR Spread. The chart
included in Section 2.4(c) of the Loan Agreement is hereby deleted in its entirety and the following new chart is substituted in its place: 
  

			
	 Leverage Ratio
	  	LIBOR Spread
Applicable Basis Points
per annum
	 Less than 1x
	  	100 basis points
	 Equal to or greater than 1x but less than 1.5x
	  	125 basis points
	 Equal to or greater than 1.5x but less than 2x
	  	150 basis points
	 Equal to or greater than 2x but less than 2.5x
	  	200 basis points
	 Equal to or greater than 2.5x but less than 3.0x
	  	225 basis points
	 Greater than 3.0x
	  	300 basis points

 The “LIBOR Spread” shall be: (i) for the period commencing on the Amendment Date and continuing through, but
not including, the final day of the Quarter End in which the Borrower’s one-time Extraordinary Expenses comprise less than twenty-five percent (25.0%) of Borrower’s Consolidated EBITDA (“Spread Adjustment Date”), three
hundred (300) basis points per annum. 
 SECTION 2 

CONDITIONS TO EFFECTIVENESS OF AMENDMENT 

2.1     Conditions to Effectiveness. This Amendment shall become effective as of the date (the
“Amendment Date”) when each of the following conditions is met (all instruments, documents and agreements to be in form and substance satisfactory to Administrative Agent and Lenders): 

(a)     Receipt by the Administrative Agent of this Amendment duly and properly authorized, executed and delivered by each
of the respective parties to this Amendment. 
 (b)     Receipt by the Administrative Agent of certified copies of
(i) resolutions of Borrower’s board of directors authorizing the execution, delivery and performance of this Amendment and (ii) Borrower’s certificate of incorporation and by-laws. 

(c)     Receipt by the Administrative Agent of an incumbency certificate for Borrower identifying all Authorized Officers,
with specimen signatures. 
 (d)     Receipt of a certification by an officer of Borrower that, after giving effect to
this Amendment, there has not occurred any Post-Closing Material Adverse Effect. 
 (e)     Receipt of the Lien
searches. 
 (f)     Payment by Borrower of the Amendment Fee. 

(g)     Payment by Borrower of all of the Administrative Agent’s reasonable legal fees and expenses incurred in
connection with the preparation and negotiation of this Amendment. 

  
 2 

 SECTION 3 

REPRESENTATIONS AND WARRANTIES 

3.1     Representations and Warranties. Borrower represents and warrants to the Administrative Agent and the
Lenders as follows: 
 (a)     The making and performance of this Amendment will not violate any Requirement of Law, or
the charter, minutes or bylaw provisions of Borrower, or violate or result in a default (immediately or with the passage of time) under any material contract, agreement or instrument to which Borrower is a party, or by which Borrower is bound.
Borrower is not in violation of any term of any material agreement or instrument to which it is a party or by which it may be bound which violation has or could reasonably be expected to have a Material Adverse Effect, or of its charter, minutes or
bylaw provisions. 
 (b)     Borrower has all requisite power and authority to enter into and perform this Agreement and
to incur the obligations herein provided for, and has taken all proper and necessary action to authorize the execution, delivery and performance of this Amendment. 

(c)     This Amendment, when delivered, will be valid and binding upon Borrower, and enforceable in accordance with their
respective terms except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium and similar laws affecting the enforcement of creditors’ rights generally and by general equitable principles. 

(d)     The execution, delivery and performance by Borrower of this Amendment does not require any approval or consent of,
or filing with, any governmental agency or authority other than those already obtained, if any. 
 (e)     The
representations and warranties contained in Section 4 of the Loan Agreement and the other Loan Documents are true and correct in all material respects as of the Amendment Date as though made on and as of the Amendment Date, except to the
extent that such representations and warranties specifically refer to an earlier date, in which case they shall be true and correct as of such earlier date and except to the extent of changes resulting from transactions contemplated or permitted by
this Amendment and changes occurring in the ordinary course of business which singly or in the aggregate do not have a Material Adverse Effect. For purposes of this Section 3, the representations and warranties contained in
Section 4.7 of the Loan Agreement shall be deemed to refer to the most recent financial statements furnished pursuant to Section 5.14(a) of the Loan Agreement. 

(f)    After giving effect to this Amendment, no Default or Event of Default under the Loan Agreement has occurred and is
continuing. 
 SECTION 4 

MISCELLANEOUS 

4.1     Amendment Fee. At Closing, Lenders shall have fully earned and Borrower shall unconditionally pay to
Lenders, a non-refundable fee with respect to this Amendment (the “Amendment Fee”) of Ninety-Two Thousand One Hundred Twenty-Five and 00/100 Dollars ($92,125.00). 

4.2     Ratification and Confirmation. Except as expressly amended by this Amendment, the Loan Agreement, the other
Loan Documents and all documents, instruments and agreements related thereto are hereby ratified and confirmed in all respects and shall continue in full force and effect. This Amendment and the Loan Agreement shall hereafter be read and construed
together as a single document, and all references in the Loan Agreement, any other Loan Document or any agreement or instrument related to the Loan Agreement shall hereafter refer to the Loan Agreement as amended by this Amendment. 

  
 3 

 4.3     Governing Law. THIS AMENDMENT, AND ALL MATTERS ARISING OUT OF
OR RELATING TO THIS AMENDMENT, AND ALL RELATED AGREEMENTS AND DOCUMENTS, SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE SUBSTANTIVE LAWS OF THE STATE OF FLORIDA. THE PROVISIONS OF THIS AMENDMENT AND ALL OTHER AGREEMENTS AND DOCUMENTS
REFERRED TO HEREIN ARE TO BE DEEMED SEVERABLE, AND THE INVALIDITY OR UNENFORCEABILITY OF ANY PROVISION SHALL NOT AFFECT OR IMPAIR THE REMAINING PROVISIONS WHICH SHALL CONTINUE IN FULL FORCE AND EFFECT. 

4.4     Successors and Assigns. This Amendment shall inure to the benefit of and be binding upon the successors and
assigns of each of the parties. 
 4.5     Duplicate Originals. Two (2) or more duplicate originals of this
Agreement may be signed by the parties, each of which shall be an original but all of which together shall constitute one and the same instrument. 

[SIGNATURES TO FOLLOW ON SEPARATE PAGE] 

  
 4 

 WITNESS the due execution of this Sixth Amendment to Second Amended and Restated Loan
Agreement as a document under seal as of the date first written above. 
  

			
	RTI SURGICAL, INC., as Borrower
		
	By:	 	 /s/ Robert P Jordhein

	Name:	 	Robert P. Jordheim
	Title:	 	Interim CEO

 (Signature Page to Sixth Amendment to Second Amended and Restated Loan Agreement) 

  
 5 

 
			
	TD BANK, N.A., as Administrative Agent
		
	By:	 	 /s/ James G. Hanning

	Name:	 	James G. Hanning
	Title:	 	Senior Vice President
	
	TD BANK, N.A., as Lender
		
	By:	 	 /s/ James G. Hanning

	Name:	 	James G. Hanning
	Title:	 	Senior Vice President
	
	REGIONS BANK, as Lender
		
	By:	 	 /s/ Philip Dermody

	Name:	 	Philip Dermody
	Title:	 	Vice President

 (Signature Page to Sixth Amendment to Second Amended and Restated Loan Agreement) 

  
 6Consultant Agreement

 Exhibit 10.39 

CONSULTANT AGREEMENT 
 This CONSULTANT
AGREEMENT (“Agreement”), effective on the 1ST day of February, 2017 (“Effective Date”), is by and between Caroline A. Hartill, an individual whose address is
642 Statenville Court, Ocoee, Florida 34761 (“Consultant”) and RTI Surgical, Inc., a Delaware corporation with a principal address of 11621 Research Circle, Alachua, FL 32615 (“RTI”) (each individually a
“Party”, and collectively the “Parties”). 
 WHEREAS, RTI is involved with the processing and distribution of
tissue for surgical implantation around the world, and seeks to promote the advancement of medical technologies related to medical devices and to tissue implantation, the enhancement of safe and effective use of medical technologies related to
tissue implantation and medical devices, the encouragement of research and education, and the fostering of charitable donations and giving (the “Mission”); 

WHEREAS, Consultant possesses and wishes to offer certain knowledge and expertise to RTI which may be of assistance to the Mission; and

 WHEREAS, RTI desires to receive certain knowledge from the Consultant which would be of assistance to RTI. 

NOW, THEREFORE, in consideration of the foregoing and the mutual covenants contained herein, RTI and Consultant agree as follows: 

1 – CONSULTING MATTERS 

1.1     Consultant shall provide consulting services (“Services”) as requested in writing by RTI in the Schedule
of Services, a copy of which is attached hereto and incorporated herein by reference as Exhibit A. The Services to be provided by Consultant may be adjusted from time to time by amending the Schedule of Services as mutually agreed to in
writing by the Parties. The exact services to be rendered shall be as directed by the Chief Executive Officer of RTI (including any Interim Chief Executive Officer) or his or her designee. 

1.2     Consultant shall perform the Services in a professional manner, in compliance with all applicable federal, state,
local and foreign laws, rules and regulations (“Laws”). 
 2 – COMPENSATION 

 

	 	2.1    	Consultant shall receive the following compensation for Services performed hereunder, as requested by RTI: 

  

	 	2.1.1	Seven Thousand Five Hundred dollars ($7,500.00) per month for the first three months of the Term (as defined below). It is understood that the Consultant shall not be required to perform more than 20 hours of
service for RTI in any month. Consultant will notify RTI’s designee upon having exhausted the 20 hour allotment of time for the month. Additional hours in a given month as agreed to by Consultant and RTI shall be compensated as provided for
below at an hourly rate of $375. After the initial three-month period, Consultant’s services will be “on request” (as contemplated by Section 1.1 above) at an hourly rate of $375.00 for the remaining six months of the Term (as
defined below). 

  
 1 

	 	2.1.2	Reimbursement for reasonable and documented out-of-pocket expenses incurred by Consultant in connection with performance of the Services. 

 

	 	2.1.3	All Consultant travel plans relating to this Agreement must be pre-approved by RTI. Consultant will be entitled to reimbursement of actual travel expenses in accordance with RTI’s travel policy in effect at the
time of travel. It is understood that all air travel will be directly billed to the Company and that any cumulative air travel of eight hours or more shall be in business class (or the equivalent). 

 

	 	2.1.4	Consultant shall bill travel time at the rate of $187.50 per hour, capped at eight hours per one way trip outside of North America and four hours per one way trip inside of North America. 

2.2     Consultant shall provide an invoice to RTI within thirty (30) days of Services rendered. The invoice shall at
a minimum specify (1) the date(s) on which Services were rendered, (2) a detailed description of the Services performed on the corresponding date, (3) the time spent rendering such services measured in 0.1 hour increments, and
(4) receipts for out-of-pocket expenses. 
 2.3     All undisputed amounts per Consultant’s invoice shall be
due and payable net thirty (30) days of RTI’s receipt of invoice. 
 3 - INTELLECTUAL PROPERTY MATTERS 

3.1     For the purposes of this Agreement, “Work Product” is defined as all work product, deliverables,
devices, inventions (whether or not patentable or reduced to practice), ideas, information and works of authorship (whether in written or other form and whether or not patentable or protectable by copyright), and know-how that have been discovered,
developed or otherwise created by Consultant as a result of performance under this Agreement, or through the use of knowledge or information obtained from RTI under this Agreement or previous employment with RTI (including its subsidiaries and
affiliates). Consultant shall disclose all Work Product to RTI. Work Product comprised of copyrightable works shall be deemed work made for hire for the benefit of RTI. Consultant acknowledges all Work Product, and all associated patent, copyright,
trademark, trade secret and other intellectual property rights embodied in such Work Product, or otherwise created by Consultant in the course of performing hereunder (“IP Rights”), shall be the exclusive property of RTI. Consultant
further acknowledges and agrees that RTI may, in its sole discretion, create derivative works from such Work Product, including, but not limited to, audio recordings, audiovisual recordings or any other form of derivative work in which such Work
Product may be recast, transformed or adapted. Such derivative works shall also be the exclusive property of RTI. Consultant is not granted any rights, whether expressly, implied or by estoppel, to such Work Product, derivative works or IP Rights.
To the extent exclusive right, title and interest in and to such Work Product, derivative works and IP Rights do not reside exclusively with RTI by operation of law or this Agreement, Consultant agrees to and hereby does assign to RTI all right,
title and interest in and to such Work Product, derivative works and IP Rights. To the extent such Work Product, derivative works and/or IP Rights cannot be assigned to RTI, Consultant agrees to and hereby does waive all rights of Consultant in and
to such Work Product, derivative works and IP Rights. Consultant will cooperate with all requests of RTI to perfect the assignments and waivers set forth in this Section, including cooperation in the form of execution and filing of additional
assignment documents and patent applications. 

  
 2 

 3.1.1     Consultant represents and warrants that all Work Product shall be
the original work of Consultant and that such Work Product, and Consultant’s provision of the Services hereunder, do not infringe or misappropriate the intellectual property rights of any third party. 

3.2     During the Term (as defined below), as may be extended, and for a period of five (5) years following the
termination or expiration of this Agreement, Consultant agrees to keep in confidence and not use any Confidential Information in any manner whatsoever, other than for the sole purpose of assisting RTI pursuant to this Agreement. Without limiting the
generality of the foregoing, Consultant shall not use any Confidential Information for the purposes of trading securities. As used in this Agreement, “Confidential Information” means the Work Product, as well as RTI trade secrets,
formulas, processes, methods, know-how and other information related to tissue engineering and surgical implants including, but not limited to, allograft and xenograft tissue grafts, and associated patents and patent applications, trade secrets, know-how, inventions, surgical instruments, technical data, drawings or specifications, testing and/or production methods, business or financial information, research and development activities, product and
marketing plans, donor information, medical records, and customer and supplier information, which are proprietary and of a confidential nature, and when furnished, shown or disclosed to Consultant are specifically designated in writing or orally
(followed by a written confirmation and summary) as “confidential”, or which are of such nature and character that a reasonable person in the trade would understand it to be confidential without the necessity of it being so designated. The
obligations of Consultant under this Section 3 shall survive expiration or termination of this Agreement. 

3.3     Consultant shall not disclose, publish, communicate, or reveal RTI’s Confidential Information to any third
party unless: 
  

	 	a.	express prior written permission is given by RTI and only after such third party executes an agreement with contractual obligations of confidentiality and non-use with respect to such Confidential Information that are
at least as protective as those contained in this Agreement, and provided that Consultant remains ultimately responsible for such third party’s acts and omissions with respect to such Confidential Information; or 

 

	 	b.	in the event Confidential Information is required to be disclosed to comply with applicable Laws, or with a court or administrative order, Consultant shall (i) provide RTI with immediate notice upon learning that
such disclosure is required, (ii) use best efforts to assist RTI in taking all reasonable and lawful actions as deemed prudent by RTI to obtain confidential treatment for the Confidential Information for which disclosure is sought, and
(iii) minimize the extent of such disclosure. 

 3.4.     The provisions of this Agreement regarding
confidentiality and non-use of Confidential Information will not apply to, and Confidential Information does not include, information which: 
  

	 	a.	was independently developed or discovered by Consultant without use or benefit of RTI’s Confidential Information, as demonstrated by Consultant’s written records; 

  
 3 

	 	b.	is already available to the public; 

  

	 	c.	becomes available to the public through no fault of the Consultant; or 

  

	 	d.	is provided to Consultant without obligations of confidentiality and non-use by a third party having the right to so provide such information. 

Notwithstanding anything herein to the contrary, Consultant shall remain bound to any and all obligations of confidentiality for any knowledge
gained under previous employment with RTI or its subsidiaries or affiliates. 
 3.5     Consultant shall not publish or
share any Work Product or Confidential Information developed or received under this Agreement without the prior written consent of RTI. 

3.6     Upon the expiration or termination of this Agreement, or within ten (10) days from receipt of request by RTI,
Consultant shall return to RTI all originals, copies, and summaries of documents, material, and other tangible manifestations of Work Product and Confidential Information in the possession or control of Consultant, and destroy all intangible
manifestations thereof (e.g., electronic files). The obligation of Consultant to return Work Product and Confidential Information to RTI and to destroy intangible manifestations thereof shall survive until fulfilled. 

3.7     Consultant acknowledges that RTI processes and distributes allograft and xenograft tissue products for
transplantation throughout the world and stipulates that the restrictions set forth herein are necessary to protect the legitimate business interests of RTI in guarding trade secrets and patentable subject matter, preserving the goodwill of its
customers and business, preventing solicitation of its customers, and preventing the unauthorized use of its Confidential Information and the Work Product created hereunder. 

4 - TERM AND TERMINATION 

4.1     The term of this Agreement shall commence on the Effective Date and continue until September 30, 2017 (the
“Term”), unless otherwise terminated early as set forth in Section 4.2 herein. This Agreement may be extended with the mutual written agreement of the Parties. 

4.2     Either Party hereto may terminate this Agreement at any time, with or without cause, by providing the other Party
with thirty (30) days’ advance written notice. Sections 3, 4.2 and 5 herein shall survive the termination or expiration of this Agreement. The expiration of outstanding options shall be governed by Section 4 of the Executive
Separation Agreement between RTI and Hartill. 
 5 – GENERAL PROVISIONS 

5.1     Consultant represents and warrants that she is not cognizant of any issues that would be a conflict of interest
with the terms and provisions of this Agreement or Consultant’s 

  
 4 

 
performance hereunder. In the event RTI or Consultant identifies a conflict of interest issue, the identifying Party will immediately notify the other Party in writing, and the Parties will work
together to rectify the conflict of interest issue. Any such conflict of interest shall be resolved to the satisfaction of RTI within forty eight (48) hours of such notice, or this Agreement is otherwise immediately terminable by RTI in its
sole discretion. 
 5.2     This Agreement may not be transferred or assigned by the Consultant, in whole or in part,
except with the prior written consent of RTI. RTI may in its sole discretion assign this Agreement or its rights hereunder. Notwithstanding the above, the Consultant may assign this Agreement to Regulatory Strategies LLC (“RSL”) upon
written notice to RTI. However, at all times during the term the Consultant must: (a) personally perform all services required under this Agreement; (b) remain the only equity holder of RSL; (c) remain personally liable for the
performance of all obligations due to RTI under this Agreement of RSL and (d) remain bound by the terms of this Agreement, including, without limitation, those set forth in Section 3. After the written notification of assignment has been
received by RTI, RTI shall direct all payments under this Agreement to RSL. 
 5.3     This Agreement is governed by and
shall be construed and enforced in accordance with the laws of the State of Florida, without regard to conflict of law rules. Venue for any legal proceeding or action at equity or law arising out of or for purposes of this Agreement shall lie in the
state courts of Alachua County, Florida, or the United States District Court for the Northern District of Florida, Gainesville Division, and Consultant agrees that such courts shall have personal jurisdiction over Consultant and hereby waives any
objection thereto. The prevailing Party in any dispute arising under, out of, or in relation to this Agreement shall be entitled to recover reasonable attorneys’ fees and costs from the non-prevailing Party, including, as applicable, any cost
of appeal. 
 5.4     Nothing in this Agreement shall be construed as granting by implication, estoppel, or otherwise,
any license or rights under patents, trade secrets, know-how, copyrights, or other intangible rights of RTI other than those specifically set forth herein. 

5.5     The Parties do not intend that this Agreement shall confer on any third party any right, remedy or benefit or that
any third party shall have any right to enforce any provision of this Agreement. 
 5.6     OTHER THAN ANY WARRANTY
EXPRESSLY MADE IN THIS AGREEMENT, RTI MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY, NON-INFRINGEMENT OR FITNESS FOR A PARTICULAR PURPOSE. TO THE FULLEST EXTENT
PERMISSIBLE UNDER APPLICABLE LAW, IN NO EVENT SHALL (A) RTI BE LIABLE HEREUNDER FOR ANY INDIRECT, CONSEQUENTIAL, SPECIAL, EXEMPLARY OR PUNITIVE DAMAGES, REGARDLESS OF WHETHER RTI KNEW OF THE POSSIBILITY OF SUCH DAMAGES; OR (B) RTI’S
AGGREGATE LIABILITY HEREUNDER EXCEED THE AMOUNTS ACTUALLY PAID BY RTI TO CONSULTANT HEREUNDER. 
 5.7     The right of
either Party to terminate this Agreement, as provided under Section 4 herein, shall not be an exclusive remedy, and either Party shall be entitled, if the circumstances warrant, alternatively or cumulatively, to damages for breach of this
Agreement, or to an order or injunction requiring performance of the obligations of this Agreement or to any other remedy available at law or equity. 

  
 5 

 5.8     This Agreement constitutes the entire agreement and understanding of
the Parties with regard to the subject matter hereof and supersedes all prior discussions, negotiations, understandings and agreements between the Parties concerning the subject matter hereof. This Agreement may be amended only by written agreement
of the Parties hereto. If any term of this Agreement is held by a court of competent jurisdiction to be invalid or unenforceable, then this Agreement, including all of the remaining terms, will remain in full force and effect as if such invalid or
unenforceable term had never been included. 
 5.9     In the event any portion of this Agreement may be deemed less
stringent than applicable Laws, regulations, or official guidance from an applicable governmental authority, the Parties agrees to confer and negotiate in good faith to amend this Agreement to comply with the more stringent standard. 

5.10     Each Party to this Agreement hereby agrees to execute, acknowledge and deliver all such further instruments as
may be necessary or appropriate to carry out the intent and purposes of this Agreement. 
 5.11     The headings
contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. 

5.12     Neither party shall be responsible or liable to the other party for nonperformance or delay in performance of any
terms or conditions of this Agreement, except for those relative to the protection of proprietary rights, due to circumstances beyond the control of the nonperforming or delaying party including, but not limited to, acts of God, acts of government,
wars, riots, third party criminal acts, strikes or other labor disputes, shortages of labor or materials, fires and floods; provided the nonperforming or delaying party provides to the other party written notice of the existence and reason for such
nonperformance or delay. Notwithstanding the foregoing, the nonperformance or delay by any party in excess of thirty (30) days shall constitute cause for termination of this Agreement with such notice given in writing by one Party to the other.

 5.13     Any notice or other communication required under this Agreement shall be in writing and delivered to the
other Party as follows: 
  

					
	 Consultant:
	  		  	
			
	Caroline A. Hartill	  		  	
	642 Statenville Court	  		  	
	Ocoee, FL 34761	  		  	
			
	RTI:	  	With copy to:	  	
			
	Chief Executive Officer	  	Legal Department	  	
	RTI Surgical, Inc.	  	RTI Surgical, Inc.	  	
	11621 Research Circle	  	11621 Research Circle	  	
	Alachua, FL 32615	  	Alachua, FL 32615	  	

 All notices shall be deemed duly served on the date delivered to the other Party at the address stated above, whether in
person, by certified mail, postage prepaid, return receipt requested, or sent by Federal Express (or other similar recognized courier) postage prepaid. Either Party may change its address for purposes of this Agreement by giving the other Party
written notice of such as provided herein. 

  
 6 

 5.14     RTI and Consultant each acknowledge that they are independent
contractors with regard to the subject matter hereof. Nothing in this Agreement shall be interpreted or construed as creating or establishing the relationship of employer and employee between RTI and Consultant. Both Parties acknowledge that
Consultant is not an employee of RTI for state or federal tax purposes, workers’ compensation, or any other purpose or benefit. Neither Consultant nor RTI shall have any right to enter into any contract or commitment in the name of, or on
behalf of the other, or to bind the other in any respect whatsoever. 
 5.15     This Agreement may be executed in
several counterparts, each of which shall be deemed an original, and all of which taken together shall constitute but one and the same instrument. 

[Signature Page Follows] 

  
 7 

 IN WITNESS WHEREOF, the Parties have caused this instrument to be executed. 

 

									
	Caroline A. Hartill	 	 	 	RTI Surgical, Inc.
					
	 Signature:
	 	 /s/ Caroline A. Hartill
	 		 	By:	 	 /s/ Robert P Jordhein

		 		 		 	Name:	 	Robert P. Jordhein
		 		 		 	Title:	 	Interim President and Chief Executive Officer
	 Date:
	 	January 31, 2017	 		 	Date:	 	January 31, 2017

  
 8 

 EXHIBIT A 

Schedule of Services 
 Consulting relating
to Regulatory Affairs, Quality Assurance and Clinical matters. 

  
 9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}]]